(R)-(+)-Anatabine

(R)-(+)-Anatabine

• CAS Number: 126454-22-6
• UNSPSC Description: (R)-(+)-Anatabine is an less active R-enantiomer of Anatabine. Anatabine is a potent α4β2 nAChR agonist[1]. Anatabine inhibits NF-κB activation lower amyloid-β (Aβ) production by preventing the β-cleavage of amyloid precursor protein (APP). Anatabine has anti-inflammatory effects and has the potential for neurodegenerative disorders treatment[2][3][4].
• Target Antigen: Amyloid-β; nAChR; NF-κB
• Type: Reference compound
• Related Pathways: Membrane Transporter/Ion Channel;Neuronal Signaling;NF-κB
• Applications: COVID-19-immunoregulation
• Field of Research: Inflammation/Immunology; Neurological Disease
• Assay Protocol: https://www.medchemexpress.com/r-plus-anatabine.html
• Solubility: 10 mM in DMSO
• Smiles: [C@H]1(C2=CC=CN=C2)CC=CCN1
• Molecular Weight: 160.22
• References & Citations: [1]Jothi L. Nallasivam, et al. Synthetic modifications of bifunctional homoallylamines: Synthesis of 2-arylpiperidines, (R)-anatabine and (R)-anabasine. An International Journal for Rapid Communication of Synthetic Organic Chemistry. Volume 49, 2019-Issue 21: 2815-2822.|[2]Paris D, et al. Anatabine lowers Alzheimer's Aβ production in vitro and in vivo. Eur J Pharmacol. 2011 Nov 30;670(2-3):384-91.|[3]Xing H, et al. A Pharmacological Comparison of Two Isomeric Nicotinic Receptor Agonists: The Marine Toxin Isoanatabine and the Tobacco Alkaloid Anatabine. Mar Drugs. 2020 Feb 11;18(2). pii: E106.|[4]eo EJ, et al. Phytochemicals as inhibitors of NF-κB for treatment of Alzheimer's disease. Pharmacol Res. 2018 Mar;129:262-273.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported